Study of oral neurokinin-1 antagonist, aprepitant for prevention of nausea and emesis in patients receiving chemotherapy including cisplatin for gastric cancer.
Not Applicable
- Conditions
- gastric cancer
- Registration Number
- JPRN-UMIN000004175
- Lead Sponsor
- Division of gastroenterologic surgery, Kanazawa University
- Brief Summary
Addition of aprepitant to standard antiemetic therapy was effective in gastric cancer patients undergoing treatment with cisplatin and S-1.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
1) patients with serious hepatic insufficiency or renal failure. 2) patients with emesis within 24 hours before first administrating of cisplatin. 3) patients who were administered antiemetic drugs within 48 hours before first administrating of cisplatin. 4) patients with emetic factor except for chmotherapy 5) patient who was intended radiation therapy 6) patients judged inappropriate for this study by physicians. 7) patients who received Pimozide.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method